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Resumo 
Nos últimos anos, tem havido um enorme interesse no desenvolvimento de fármacos para o 
tratamento de diversas doenças. Estima-se que cerca de 1.5 mil milhões de pessoas em todo o mundo 
sofrem, ou virão a sofrer, de algum tipo de distúrbio do sistema nervoso central (SNC), existindo, por 
isso, uma grande necessidade de encontrar formas de tratar estas doenças, as quais ainda permanecem 
difíceis de compreender. 
A libertação de fármacos para o cérebro tem sido considerada como uma possível terapia para o 
tratamento de tumores cerebrais e de doenças neurodegenerativas. No entanto, o acesso ao cérebro, 
pela via endovenosa, é bastante limitado devido à existência de uma barreira altamente dinâmica e de 
permeabilidade selectiva, a barreira hematoencefálica (BHE), que protege o cérebro, controlando a 
entrada de solutos no SNC. 
Com base em Nanotecnologia, nanopartículas multi-funcionais com tamanho controlado e geometria 
uniforme têm sido desenvolvidas como sistemas de libertação de fármacos, com o aumento do local dos 
fármacos nos locais alvo, minimizando os seus efeitos colaterais. 
Este projeto centra-se sobre o desenvolvimento de um sistema à base de péptido, para formar 
nanoestruturas do tipo micelar, com o objetivo de estudar o seu potencial para atuar como 
nanotransportador e conduzir fármacos para o cérebro. 
O tamanho e a estabilidade das micelas são características fundamentais a ter em conta neste 
estudo, assim como, ensaios de libertação de fármacos e estratégias para melhorar o sistema, como 
por exemplo, direcionando-o para o local de destino. 
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Abstract 
In recent years, there has been a considerable interest in developing drugs for the treatment of 
various diseases. It is estimated that about 1.5 billion people worldwide will suffer from some type of 
central nervous system (CNS) disorder at some point, so, there is a strong demand to treat these 
diseases, which still remain difficult to understand. 
Drug delivery into the brain has been recognized as a possible therapy to treat brain tumors or 
neurodegenerative diseases. However, the access to the brain, intravenously, is a great challenge, due 
to the highly selective and dynamic permeability barrier, which protects the brain controlling the entry 
of solutes into the CNS, the blood-brain barrier (BBB).  
Based on nanotechnology, nanoparticles with controlled size, uniform shape and carrying multi-
functionalities have been developed as drug delivery systems, increasing the drugs local concentration 
at target sites and minimizing their side effects. 
This project focus on the development of a peptide-based system, able to form micelle-like 
nanostructures in order to study their potential to serve as nanocarrier and deliver drugs into the brain  
The size and stability of the micelles are essential features to be considered in this study, as well as 
drug delivery assays and strategies to improve the system, for example, directing it to the target 
location. 
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  Chapter 1
 
Introduction 
Due to significant advances in healthcare technologies, people are living longer contributing for the 
increase of an aged population. Associated to this aged population, is a high incidence of neurological 
disorders, which have an enormous social impact and are an important cause of morbidity, contributing 
to 12% of global deaths. [1] 
Neurological disorders are any disorder of the body’s nervous system which can include 
neuropsychiatric disorders and injuries that have neurological sequels. [1] Neurological disorders within 
the neuropsychiatric group, like epilepsy, Parkinson’s disease, multiple sclerosis, Alzheimer and other 
dementias, are the main cause of mental, physical and social disability, affecting a great number of 
persons. 
Since there are no effective therapies for many of them yet, [1] probably due to the inadequate 
understanding of the nervous system, treating these diseases is a major challenge and drug delivery 
into the brain has been recognized as a possible therapy. 
Delivering drugs at controlled rate and targeted transport are emerging to solve the limitations of 
conventional drugs and to increase the therapeutic efficiency. Drug delivery systems have been 
designed to protect drugs from degradation. They must be biocompatible, so that body’s defense 
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system does not recognize them as foreign particles and localized at target diseased areas, minimizing 
their side effects. [2] 
Significant progress has been observed in this area, thanks to advances in nanotechnology, which uses 
engineered materials or devices, typically ranging from 1 to 100 nanometers that can interact with a 
biological system with a high degree of specificity. [3] 
Drug delivery systems have been classified according to the routes of delivery, type of delivery 
vehicles and the employed strategies to reach the target. [4] 
Drugs can be administered in different ways depending on the type of disease, the desired effect and 
the available product. [5] Routes of administration can be classified whether the effect is local and the 
drug is applied directly to the organ affected (topical route), which is not an option in cases of CNS 
disorders, or systematic, targeted to the diseased organ (enteral or parenteral route). 
The administration through the gastrointestinal tract is enteral, including oral, rectal or sublingual. 
The oral route is, generally, the most used and highly preferred due to the ease of administration and 
the lowest cost. However, some drugs can cause problems, like irritation of the gastrointestinal tract, 
can be degraded by digestive enzymes before they reach the target site or cannot effectively reach the 
blood stream due to their high molecular size or charge, like proteins and peptides. 
The term parenteral means the introduction of drugs into the patient through intramuscular, 
intravenous, intra-arterial and subcutaneous injection and gets advantage of rapid onset of action and 
avoid the oral administration problems, mentioned above. [5, 6] 
Drug delivery strategies established to act in the central nervous system (CNS) to treat neurological 
disorders or brain tumours have an additional barrier unlike in the other therapeutic areas, the blood 
brain barrier (BBB). Thus, these drugs to be administered intravenously must have the ability to cross 
this barrier. However, the strategies already developed are proved invasive and non-specific to the 
target, including osmotic disruption to increase the BBB permeability, direct introduction of the agent 
in the CNS or intracerebral implantation. Besides the associated high risk of complications, these 
procedures are rather expensive. [7] 
To solve these limitations, new approaches are emerging, using nanoparticles with controlled size, 
uniform shape and carrying multi-functionalities in order to cross the BBB noninvasively facilitating 
their delivery in to the brain. 
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1.1. Blood Brain Barrier (BBB) 
CNS has its own security system, highly selective and dynamic permeability barrier that allows the 
entry of essential nutrients, while blocking invading organisms and unwanted substances, the blood–
brain barrier. 
Although the BBB has an important function to protect the brain from toxic compounds, it is also the 
main challenge for drug delivery into the brain, since it represents the major barrier for drug transport 
into the brain via the blood circulation. 
This section presents a better understanding associated to the physiology and biology of the major 
barrier of our body and its changes under pathological conditions. 
 
1.1.1. Physiology and biology 
Brain endothelial cells (BECs), which form the walls of capillaries, are different from endothelial cells 
in the other organs. They exhibit lower permeability and pinocytic activity, no fenestrations and 
possess a superior number of mitochondria, resulting in a more intense metabolic activity. [8] 
BECs are characterized by the presence of interconnections between adjacent cells, like gap 
junctions that mediate intercellular communication [9], adherens junctions (AJs) and tight junctions 
(TJs), which are responsible for the high transendothelial electrical resistance that reduce the aqueous 
based paracellular diffusion [10] and prevent transcapillary passage of ions, hydrophilic compounds and 
macromolecules, such as proteins. 
As a result of these anatomical features, these cells form a cellular barrier that constrains the 
passage of molecules and cells between the blood and brain. 
The BBB is a natural protection of the brain against adverse agents, allowing the neurons to 
communicate with each other through chemical and electrical signals, and it keeps the interstitial fluid 
composition stable so that the neurons can maintain a controlled electric potential support. [11] The 
functional unit of BBB, shown in figure 1.1, consists not only by capillary endothelial cells and neurons 
but also by several other components such as pericytes, basal lamina components, perivascular 
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microglial cells, astrocytes. Pericytes and perivascular astrocytes in contact with the endothelium [12] 
are essential to maintain the equilibrium conditions in the interstitial space [11] and pericyte 
dysfunction can cause the BBB to snap leading to several brain disorders. 
BBB also controls the recruitment of leukocytes and regulates the innate immune response acting as 
the boundary between central and peripheral immune systems. [6] 
 
Figure 1.1- Representation of BBB and other components of neurovascular unit including circulating 
cells. Adapted from [11] 
 
1.1.2. Transport mechanisms across the BBB 
The unique biological characteristics of the BBB are responsible for its multiple dynamic functions 
acting as a transport, physical, enzymatic and immunological barrier [13] and capable of responding to 
a wide range of regulatory signals from both sides contributing to CNS homeostasis. [6] 
There are several transport pathways by which solutes can move in and out of the brain, including 
passive and facilitated diffusion, which proceed from low to high concentrations, and active transport, 
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that requires adenosine triphosphate (ATP) as a chemical energy source and conducts movement 
against the concentration gradient. [14] 
Diffusion of substances into the brain may be performed by passing through the intercellular 
space between the cells (paracellular diffusion) or through a cell (transcellular diffusion). Paracellular 
diffusion (figure 1.2 (a)) does not occur in great extent at the BBB, such as small water-soluble 
molecules that passively diffuse through the TJs, unlike the small lipid soluble molecules that 
penetrate transcellulary (figure 1.2 (b)) by dissolving in their lipid plasma membrane.  
Besides the concentration differences between both sides, lipophilicity and molecular weight are 
other parameters that can affect the diffusion. Highly lipophilic and small substances (less than 500 Da) 
such as small inorganic molecules (O2, CO2, H20), are highly permeable.  
Nevertheless, poorly permeable substances require a mediated transport that facilitates movement 
through the BBB by carrier-mediated transport, or endocytosis/transcytosis. 
In the case of carrier-mediated transport, membrane transporters, that are mostly proteins, aid the 
transport into the brain (by facilitated diffusion or active transport) and block the entry of several 
molecules. 
Essential solutes such as glucose or amino acids bind to a protein transporter (glucose transporter 
GLUT1 or amino acid transporter LAT1) which changes its conformation allowing the traffic of these 
solutes to the other side (facilitated transport) (figure 1.2 (c)). However, there are some cases in 
which substances need to be moved against concentration gradient using energy provided from ATP 
(active transport). 
ATP family of efflux transporters (ATP binding cassette- ABC) including p-glycoprotein (P-gp) and 
multidrug resistance proteins (MRPs) are responsible to prevent the permeability of several 
pharmacological agents.  
In addition of these transport systems, certain endogenous proteins and peptides pass through the 
BBB by vesicular transport and transcytosis that can be receptor- or adsorptive- mediated. 
Receptor-mediated transcytosis (RMT) such as transferring receptor (TfR), insulin receptor or 
lipoprotein receptor allows selective uptake of macromolecules. These processes are activated when a 
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ligand, for example insulin molecules, bind to cell-surface receptors invaginated into the cytoplasm 
forming a coated vesicle. (figure 1.2 (d))  
Adsorptive-mediated transcytosis (AMT), or pinocytosis route, facilitates the transport of large 
peptides such as histone, albumin and other plasma proteins by electrostatic interactions, binding the 
positively charged moiety of a peptide to the negatively charged cell membrane surface. (figure 1.2 
(e)) 
The transport of immune cells, such as monocytes or macrophages, across the BBB is designated cell-
mediated transcytosis and can be used for any type of materials, unlike the other types of transport 
mechanisms. [6, 12, 13] 
Many of the mentioned pathways across the BBB can influence drug delivery having reduced access to 
CNS when agents are less lipophilic due to the activity of ABC efflux transporters. [6] 
 
Figure 1.2- Transport mechanisms across the BBB. Adapted from [14] 
 
1.1.3. Changes in BBB in pathological or disease conditions 
The properties of the barrier can be disturbed in pathological conditions affecting its tightness and 
functions including transport mechanisms. [6, 13] Most CNS pathologies, including stroke, multiple 
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sclerosis, epilepsy, start with a sequence of events which leads to an increased BBB permeability and 
can contribute to disease progression. [6] These alterations of BBB permeability are possibly due to 
disruption of TJs, since they form the physical barrier which may be caused by an increased 
transmigration of leukocytes into the brain like it happens in inflammatory diseases. 
The integrity of BBB remains in normal aging, but the changes in the brain vasculature may make the 
BBB more vulnerable to pathological injuries. [15] 
In age-related neurodegenerative disorders, such as Alzheimer’s and Parkinson’s disease, the 
relationship between BBB dysfunction and pathology is not clear, although it has been suggested that it 
can contribute to disease progression. [16] 
Thus, this barrier can be considered a target of therapeutics to treat these diseases. However, the 
changes are not the same for all diseases and also depend on the degree of development of each 
disease being difficult to predict the effects of any particular drug. [1] 
Due to the complexity of the BBB on pathological conditions, this topic will not be described in this 
thesis, but further details can be found elsewhere. [1, 6, 15, 16] 
 
1.2. Nanocarriers as drug delivery systems 
As mentioned previously, delivery of drugs into the brain is a great challenge due to difficult 
passage across the BBB and several approaches have been studied to bypass this barrier noninvasively. 
This section focuses on delivery vehicles, namely nanocarriers, being one of the approaches to 
overcome this challenge.  
Nanocarriers are nanomaterials that can be used to transport drug molecules. Drugs can be bound in 
the form of a solid solution, dispersion, be adsorbed to the surface or chemically attached on 
nanoparticles. [17] 
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Because of their small size, they can penetrate into dense tissues, such as tumours, and can be 
functionalized in order to deliver drugs at target sites and at controlled rate.  
To this date, several nanoparticles have been developed to act as drug carriers, including inorganic 
or organic materials with advantages and some limitations, depending on the purpose. 
For nanocarriers to serve as good candidates for delivering drugs, many factors need to be considered 
such as its size (less than 100 nm); toxicity, biocompatibility and biodegradability; stability in blood; 
prolonged circulation time; controlled and target release, as mentioned previously. 
 
1.2.1. Inorganic nanocarriers 
 
 Gold nanoparticles 1.2.1.1.
Gold Nanoparticles (Au NPs) have been widely used for several applications due to their various size 
and shape. Among all the shapes, such as spherical, triangle, irregular shape, nanotriangles, 
nanoprisms and nanorods, the later having increased importance due to their specific optical and 
chemical characteristics, making them suitable for biosensing, gene delivery and photo thermal 
therapy. Gold NPs can also be used as molecular probes for imaging due to their high adsorption 
coefficient and the electron density of the gold which improves computed tomography (CT) contrast. 
They can be easily synthesised, present low cytotoxicity, are small sized and have uniform dispersion 
helping them to reach the target site. Their large surface area provides drug attachment and they were 
shown to be biocompatible. These are some more features of gold NPs that make them advantageous 
over other nanocarriers. [18] However, since it is a solid particle, encapsulation of the drug is not 
possible, leading to more complex techniques to attach the drug to the nanocarrier, implying more 
time-consuming. The major limitation of these systems, with the intention to act in the brain, is the 
lack of biodegradability, meaning accumulation into the brain, requiring surgical removal. 
 
 Superparamagnetic iron oxide nanoparticles (SPIONs) 1.2.1.2.
These nanoparticles are composed by superparamagnetic compounds which are attracted to a 
magnetic field when it is applied, but when removed they do not retain any residual magnetic 
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interactions, being unlikely to agglomerate and posing no danger of thrombosis or blockage of blood 
capillaries.   
Due to their paramagnetic features, they can be analysed by magnetic resonance imaging (MRI) and 
are advantageous for use as drug delivery vehicles because they can be guided to their target site and 
release the drug under the influence of an applied magnetic field.  
However, there are some limitations, such as their unspecific uptake by target cells and uncoated 
SPIONs have demonstrated low brain-targeting efficacy.  
The biocompatibility of these nanoparticles and their possible adverse interactions with the body are 
still under investigation. [19, 20] 
 
 Silica nanoparticles 1.2.1.3.
Silica nanoparticles are nanoshells, spherical nanoparticles consisting of a dielectric core surrounded 
by a metallic shell. Silica is typically used as core due to its high stability. [19] The biocompatibility 
and the excellent protection for their internal payload make them excellent carrier for controlled drug 
delivery applications. [21] Though, Chang et al (2007) found that, at high dosages, silica nanoparticles 
could be toxic shown by a reduction in cell viability. 
1.2.2. Organic nanocarries 
 
 Polymer-based systems 1.2.2.1.
Polymeric nanoparticles (polymeric NPs) – These nanoparticles are composed of a core polymer 
matrix in which drugs can be embedded and are made from synthetic polymers such as polyactides 
(PLA), polyglicolides (PGA) or poly(lactide-co-glycolides) (PLGA) among others or natural polymers, 
such as chitosan. [1] 
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Some studies have proven that polymeric NPs enhance drug delivery to the brain with control release 
mechanisms, namely NPs made of PLGA embedding antituberculosis drugs for brain delivery, 
demonstrating high drug levels in the brain for more days than with free drugs. [1]  
However, to cross the barrier to reach the brain, these nanoparticles have to undergo several 
modifications which add complexity and time to the process. Also, their large scale production is 
problematic. 
Dendrimers – Dendrimers are highly branched polymers with a well-defined chemical structure, 
consisting of a core or focal moiety and multiple arms which emerge from the core, with functional 
terminal groups. These play a key role in the drug entrapping ability due to their specific molecular 
structures, tightly packed in the periphery and loosely packed in the core. [19, 22] 
Thus, dendrimers can be used for drug delivery by modifying their terminal groups for drug targeting. 
[1] However, the rigidity and density of the branched units can affect drug release kinetics. [22] 
Polymeric micelles – Polymers can also be used in drug delivery enveloping drugs through 
micellization. Polymeric micelles are amphiphilic copolymers formed by self-assembly in aqueous 
solution resulting in core-shell nanostructures with a hydrophilic shell and a hydrophobic core which 
can act as reservoir for entrapping water insoluble drugs.  
Using micelles as vehicle in drug delivery has many advantages, including high drug loading capacity 
in the core and their nano-range size properties leads to a rapid cellular uptake.  
However, these systems can present some specific disadvantages such as the difficulty in polymer 
synthesis unlike the random polymers and low drug loading capacity or difficult drug incorporation 
technology, mainly in large scales. [1, 2, 22, 23]  
 
  Lipid-Based Systems 1.2.2.2.
Liposomes – The use of liposomes as drug carriers is another type of nanoparticle. Liposomes are 
vesicular structures composed of a hydrophobic lipid bilayer, made of biocompatible and biodegradable 
lipids, delimiting an aqueous core. 
The drugs can be packed within liposomes or intercalated into lipid bilayers, enabling the liposome to 
carry both hydrophilic and hydrophobic drugs and to merge with cell membrane releasing the drug. [1, 
17, 19, 24]  
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Nevertheless, the immediate uptake and clearance of the liposome by the reticuloendothelial system 
can be immediate can be a problem in using these in vivo, only being resolved with surface 
modifications. Hence, liposomes present low stability.  
Solid-lipid nanoparticles (SLN) – These lipid-based nanoparticles contain a solid hydrophobic lipid 
core in which the drugs are dissolved and can be used for several therapeutics as colloidal drug carriers 
in the place of liposome or emulsions, since these have a better stability.  
SLNs can be produced by replacing the liquid lipid oil of an emulsion process by a solid lipid and have 
the advantage of possessing more flexibility in controlling the release of the encapsulated drug 
provided by the solid matrix. [1, 17, 25] 
Besides these great advantages, they also can suffer from some disadvantages. The crystalline 
structure of the solid lipid leads to a low incorporation rate.  
 12 
1.2.3. Summary of nanocarriers for drug delivery 
Table I summarizes the main applications and main advantages and limitations of these various nanocarrier systems described in the previous 
section.  
Table I - Different classes of nanocarriers, their main applications, advantages and limitations 
Class Main Applications Advantages Limitations Schematic 
representation 
References 
Inorganic      
Gold NPs 
Chemical and biological 
sensing 
Biomedical imaging 
Tracking and drug 
delivery 
Catalysis 
Biocompatibility 
Non-cytotoxicity 
Easily synthesized 
Unique optical, physical 
and chemical properties 
Diverse/multiple shapes 
Lack of biodegradability 
Solid particle, 
complexity in attaching 
the drug  
 
 
[1, 18] 
SPIONs 
Targeted delivery of 
drugs/genes 
Thermotherapy 
Easy to manufacture 
MRI visualization of 
neuroinflammation in 
vivo 
Monitorization of the 
CNS disease progression 
Accumulation into the 
brain 
Unspecific uptake by 
target cells without 
coated  
 
[1, 17, 19, 20] 
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Silica 
Imaging 
Drug delivery 
Catalysis 
Blood immunoassay 
Optical and chemical 
properties 
High Biocompatibility 
High porosity (high 
loading efficiency) 
Toxicity  
Lack of biodegradability  
 
[1, 17, 19, 21] 
Organics      
Polymeric NPs Deliver water insoluble 
drugs 
Stability 
Controlled release 
Stimuli responsive 
Lack of biocompatibility 
Do not undergo 
significant transport 
through the BBB without 
further modifications 
 
 
[1, 26] 
Dendrimers 
Imaging 
Drug delivery 
Gene transfection 
Therapeutic treatment 
High drug carriage 
Terminal groups can be 
modified for drug 
targeting 
Rigidity and density of 
the branched units 
Cytotoxicity of the 
polymers after 
internalisation into cells 
 
[17, 27] 
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Polymeric micelles 
Drug delivery 
 
Good grade of stability 
Easy conjugation for 
active targeting 
High drug loading 
capacity 
Difficult polymer 
synthesis 
Need surface 
modifications to reach 
the target sites  
 
 
[1, 2, 28] 
Liposomes 
Drug delivery 
Cosmetic delivery 
 
Favourable safety 
profiles 
Ease of surface 
modifications 
Able to carry both 
hydrophilic and 
hydrophobic 
Short half-life 
High production costs 
Unstable in biological 
conditions   
 
[22, 24] 
 
Solid Lipid NPs 
Drug delivery 
Stability 
Large surface area 
High drug loading 
Controlled release 
Low incorporation rate 
Gelation tendency 
 
[19, 25] 
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1.2.4. Strategies to improve the functionality of the nanocarrier 
These nanocarriers have shown efficiency in pharmaceutical industry, however many of these can 
suffer from low selectivity and lack of target-ability, uncontrolled release profile and low circulation 
life in the blood stream. Therefore, several strategies to modify their surfaces have been developed to 
overcome these problems. 
The most common approaches consist on the functionalization of nanocarriers to increase stability 
and half-life circulation, target specific tissues and making them responsive to certain physiological 
stimuli such as pH and temperature. [2]  
Some possibilities of nanocarrier functionalization for brain drug delivery are represented in figure 
1.3. [1] 
 
Figure 1.3- Nanocarriers with surface-modification. Representation of drugs (can be incorporated 
within the core (payload) or conjugated to the surface), targeting molecules(antibodies, cationic 
molecules, peptide, aptamer), PEG to enhance circulation time and fluorescent probes as a tracer. 
Adapted from [1] 
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 Half-life circulation 1.2.4.1.
One of the nanocarrier properties to take into account for drug delivery through vascular route into 
the brain is its stability in the blood which means no aggregation and dissociation and longevity in 
blood circulation since the immune system such as macrophages can recognize the nanocarriers as 
foreign bodies and remove them from circulation before they achieve the target site and perform their 
action. [2, 13] 
The most widely used strategy for reduced uptake by macrophages and to solve this issue is 
PEGylation, the coating of the material with an highly flexible and hydrated poly(ethylene glycol) (PEG) 
chain. [29] 
This is because Frank F. Davis in 1977 has studied the immunogenic properties of the PEG and 
concluded that the attachment of this hydrophilic polymer to proteins controls immunogenicity and 
extends circulation time in rabbit and mice. [2, 30] 
Thus, surface functionalization of nanocarriers with PEG has become a stealth strategy to increase 
nanocarrier’s circulation half-life in which PEG molecules form a hydrophilic layer on the nanocarrier’s 
surface protecting them from interaction with blood components, designated “steric stabilization” 
effect. [29] 
However, this effect is no longer favourable when the nanocarrier arrive the target site. The drug 
entrapped in a nanocarrier should be specifically delivered into the pathological sites and this coating 
can be an obstacle, so many approaches have been developed to detach the PEG after onset at the 
target sit, described below. [29] 
 
 Molecular Targeting 1.2.4.2.
Another largest problem of many pharmaceutical agents is the lack of target-ability causing side 
effects and toxicity. Targeting strategies for drug delivery systems can be passive or active targeting. 
The increased BBB permeability on pathological conditions can be a window of opportunity for drugs 
unable to cross this barrier to reach the target in the diseased brain. [13] This selective targeting based 
on permeability, like in tumor tissues leading to enhanced permeability and retention (EPR) effect, is 
considered “passive targeting”. However, there are some limitations since the degree of BBB 
permeability may not be the same in all disorders and also depends on status of each disease. [31]  
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An “active targeting” can overcome these limitations modifying the surface of nanocarriers by 
covalent conjugation of targeting moieties, which only bind to specific receptors on the cell surface, 
leading to internalization of the nanocarrier through receptor-mediated transport, in order to ensure 
the drug is released in a specific site, such as CNS. [24] These receptors should be highly expressed 
only on specific sites so that high specificity is reached. 
Antibodies and their fragments, aptamers and other receptor ligands such as peptides and vitamins 
are potential active agents. [22] The choice of a target is a fundamental aspect in the development of 
these functionalized nanocarriers and depends on several factors such as target expression which 
determine delivery specificity, their function and biocompatibility to control potential side effects, 
binding affinity as well as size and charge and ease of modification to the surface. [22, 32] 
Several strategies have been developed by receptor-mediated transcytosis since many receptors are 
overexpressed in the brain endothelium such as TfR or low density lipoprotein receptor (LDLR). 
Many research groups have been explored transferrin as a brain delivery ligand and shows anti-glioma 
activity when conjugated with a polyphophoester hybrid micelles (Zhang et al.). However, since this 
system would have to compete with natural ligand an alternative emerged such as the conjugation with 
a monoclonal antibody (mAb). Liposome conjugated with this system transferring/antibody, the drug 
targeting was achieved. [33, 34] 
The mAb are the most widely used for targeting cancerous cells, approved by the US food and Drug 
Administration (FDA). However, due to their large size, trouble in conjugation to nanocarriers or the 
immunogenic response that can elicit itself, peptides and other small molecules have been an 
outstanding alternative to solve these limitations. [31, 35] 
Another receptor widely studied for ligand mediated targeted brain delivery is the LDLR and 
angiopep, a peptide which display higher transcytosis capacity, so that can act as ligand for targeting 
to this receptor. Results demonstrated that angiopep-modified NPs crossed the in vitro and in vivo BBB 
models more efficiently than unmodified NPs. [33, 34] 
 
 
 
 18 
 Stimuli-responsiveness 1.2.4.3.
To program its release at target sites, an additional functional group can be coupled in a 
multifunctional nanocarrier responsive to the physical or chemical alteration of the local site. [32] 
In a pathological condition some alterations are noted such as lower pH or higher temperature, 
making the injured areas, like inflamed or tumor tissues, different from normal tissue. [2, 29] Thus, 
nanocarriers survive in normal conditions and are only subjected to degradation, with consequent drug 
release, in the area of interest. [29]  
The stimulus to degrade the carrier can also be external, such as heat, magnetic field and 
ultrasound, which can be locally applied on the target tissue allowing the nanocarrier to release the 
drug only inside this area. [2, 29]  
 
1.2.5. Nanocarriers mechanisms to release drugs upon reaching CNS 
After reaching the target site, it is important to know how these nanocarriers release the drugs, 
being the mechanisms still not well understood depending on functionalization, dosages, via of 
administration, since the environment of CNS and BBB change in case of disease. 
The main mechanisms already studied in targeted brain delivery involves active targeting, using 
nanocarriers conjugated to site-specific ligands, being recently reviewed by Bareford et al. the role of 
endocytosis, which can improve the treatment of diseases like Alzheimer.  
Figure 1.4 represents the two main mechanisms of endocytosis mediated transport of nanocarrier 
systems: receptor-mediated and adsorptive-mediated. Nanocarriers conjugated to ligands which bind 
to specific receptors on BECs can be internalized via receptor-mediated (1) where they are invaginated 
forming vesicles which, due to acidification, dissociate the receptor from the ligand leading to the 
release the drug and the degradation of the nanocarrier (1b).  
The adsorption of uptake promoting apolipoproteins have been proposed as other mechanism, 
concluded by Kreuter et al that apolipoproteins B and E can adsorb the coating nanoparticles with 
polysorbate 80 and, via receptor-mediated endocytosis, could be taken up by BECs, since mimic 
lipoprotein particles. 
Adsorptive-mediated has also gained significance in drug transport, using cationized ligand 
conjugated nanocarriers to interact with surface of BECs which are negatively charged. Dos Santos et 
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al. found heparin sulphate (HS), a polyanion detected on BCEs surface, but more investigation is 
required to explore other polyanion sites to develop these systems.  
Lu et al., has incorporated plasmid pORF-hTRAIL (pDNA) into cationic albumin-conjugated PEGylated 
nanoparticles (CBSA-NP) and observed that these NPs co-localized with glycoproteins in brain and 
accumulation in tumour cells that led to their apoptosis and, significant delayed tumour growth. [36] 
 
Figure 1.4 – Endocytic mechanisms for targeted drug delivery to the brain, using conjugated 
nanocarriers. Adapted from [36] 
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Some drugs can also be delivered into the brain by carrier-mediated mechanism, since the membrane 
transporters presented in the BBB have been shown to accept drug molecules and to carry them into 
the brain. However, it is also important to take into consideration the efflux transporters which can 
exclude the drugs out of brain. It is, therefore, essential to identify all the transporters to inhibit them 
improving the drug distribution in the brain. [37]  
 
1.2.6. “Self-assembly” in nanocarriers design  
Molecular self-assembly is the organization of molecular units in a spontaneous, reversible and 
coordinated fashion to form complex structures by non-covalent interactions (hydrogen bonding, 
electrostatic and hydrophobic interactions). Many of these interactions occur in biological systems, 
such as the tertiary and quaternary structure of proteins. 
Inspired on nature, self-assembly has been increasingly studied to construct functional nanomaterials 
to cover a wide variety of applications, allowing a better structures and functional control at the 
molecular level. [38, 39] 
The self-assembled systems provide great advantages being a simple and fast process. Their ability to 
generate well-ordered 3D structures with sub-nanometer precision, due to operating at molecular 
level, without a guidance of external source, also makes it an attractive “bottom-up” strategy. 
Unlike the systems mentioned above, Brownian motion, the random movement of the particles in a 
liquid due to the collision with molecules which surround them, does the job instead of machinery to 
move and orient components. [40] 
Due to these advantages, many advances have been done in the design and fabrication of nano-scale 
materials trough peptide self-assembly.[39] 
The simple structure of peptides, their stability under various conditions and their variety of self-
assembled shapes make them the best choice for design different materials using natural building 
blocks. [41] 
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 Peptide Amphiphile as nanocarrier formed by self-assembly 1.2.6.1.
Peptides are made of amino acids, considered natural building blocks, which due to their different 
chemical nature (polar, non-polar, positively or negatively charged, aliphatic, etc.), can form a large 
number of different peptides, through the combinations of different amino acids lengths and 
sequences. [39] 
A simple category of the designed self-assembling peptides is represented by molecules that combine 
the structural and chemical properties of lipid or surfactant with the biofunctional peptide epitope and 
have the ability to self-assemble into a wide range of different nanomaterials. These peptide-based 
molecules are called peptide amphiphile (PA) and have gained wide attention because of their strongly 
amphiphilic nature, possessing a hydrophobic tail and hydrophilic head. [38, 39] 
In aqueous environment, these peptides can form structures aggregates such as nanofibers, 
nanovesicles, nanotubes, through self-assembly when the concentrations are above their critical 
aggregation concentrations (CAC) which can be detected by fluorescence methods.  
Figure 1.5 represents the requirements for a functional PA to assemble into a well-defined structure, 
i.e., with different regions, each with their role, that make it to be formed structures in an organized 
and orderly way. Region 1 includes the hydrophobic entity, consisting of a hydrophobic segment made 
from non-polar amino acids remains or alkyl chains. This region is responsible for driving self-assembly 
due to hydrophobic interactions between different tails, exposing the functional peptide group on the 
surface of the nanostructure. 
 
Figure 1.5 - Chemical structure of a representative PA molecule with their four key domains. 
Adapted from [42] 
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The hydrophobic alkyl tails also improve the thermal stability of the PAs, being PAs with longer tails 
more stable but less soluble. A study about self-assembly of PAs containing RGD cell adhesion motif, 
shows that PAs with only six carbon atom alkyl tails were not able to form gel, unlike PAs with C10, C16 
and C22 which formed gels upon acidification. [42] 
For further aggregation to occur, region 2, which have the ability to form intermolecular hydrogen 
bonds between the peptide strands consisting of a peptide sequence leading to β-sheet formation, 
determines the interfacial curvature of the self-assembled structure. Systems without this region and 
so, where there are only hydrophobic interactions, lead to formation micelles with the hydrophobic 
tails inside the core and the hydrophilic heads exposed to water, due to the dislike of tails to water. 
The influence of stability concerns the region 3, charged amino acids residues can be positively, 
negatively charged or a mixture of both. Therefore, the self-assembly of PAs can be altered changing 
the solution pH. 
The last region is where bioactive signals are presented through functional peptide epitope which can 
interact with desired target. [38, 39, 42] 
One example of aggregation of these PA molecules having these four domains is the formation of 
cylindrical nanofibre, as shown in figure 1.6 
 
Figure 1.6 – Illustration of nanofibre resulted from self-assembly of IKVAV-containing PA molecule. 
Adapted from [42] 
 
The self-assembly of PAs can be tuned and manipulated in response to a stimulus by changing the 
local environment, being useful in the production of biomaterials and in a wide range of applications 
such as drug delivery systems.  
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For all these reasons, these systems represent a better option when the focus is the design of a 
nanocarrier, having great advantages over the others nanocarrier systems, mentioned previously. The 
self-assembly of PAs leads to different functional nanostructures with multiple properties such as 
targeting ability, without complex and time-consuming techniques as in others. 
These four main regions, each with their key role, incorporated into PAs makes them an interesting 
systems for drug delivery into the brain, without the need for further modifications on the surface. 
 
1.3. Aim of the thesis  
Therefore, this project aimed to design and develop a better nanomaterial able to cross the BBB and 
reach the brain in order to deliver drugs at controlled rate and target transport, minimizing their side 
effects. 
Peptide amphiphile was synthesized to form micelles, in aqueous environment, by self-assembly. The 
micelle conditions, such as their size and stability, were studied to understand their potential, to act 
as nanocarrier, in drug delivery into the brain. 
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  Chapter 2
Materials and Methods  
2.1. Peptide Synthesis  
Peptide synthesis has been an important tool in medical areas since synthetic peptides can be used as 
therapeutic drugs or in diagnosis. 
Peptides can be synthesized by attaching the carboxylic acid group (C-terminus) of one amino acid to 
the amino group (N-terminus) of another amino acid forming an amide bond, as shown in figure 2.1. 
This process is called coupling. [43] 
 
Figure 2.1 - Generalized chemical formation of an amide bond. (R) side chain of first amino acid; (  ) 
side chain of the second amino acid; (COOH) carboxylic group; (NH2) amino group 
 
This procedure is not so simple since the diversity of the various amino acids can originate numerous 
different combinations. To make sure that the peptides are formed with the desired chain in the right 
order, the amino acids side groups should be protected to prevent side reactions. The mostly used 
protective group is Fmoc (9-fluorenylmethoxy-carbonyl), which is used for the amino protection of the 
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N-terminal In addition, many amino acid side chains must be protected as well as in the case of Lysine 
with Boc (a tertiary Butyloxycarbonyl group), for not forming undesired branched chains. 
 
Figure 2.2 - Structure of Lysine with protecting groups. Fmoc-Lys(Boc)-OH 
 
The classical approach to synthesize peptides is the synthesis in solution which has the advantage to 
detect undesirable side reactions since, at every step, the intermediate compounds can be 
characterized and isolated. However, the low yield of the intermediate peptides and the issue of poor 
solubility are limitations of this method. 
In order to solve these problems, another method was developed where insoluble polymers are used 
as a support for the peptide synthesis, known as solid-phase peptide synthesis (SPPS). 
SPPS is simple, faster and high yield approach than the classic solution phase and solves the problem 
of solubility since the growing peptide chain is only detached from the support when the process has 
been completed. In addition, it can be made by an automated peptide synthesizer leading to a good 
and quick performance or manually, in the case of the miligram scales. [43, 44] For that reason, SPPS it 
was the method of choice in this work. 
The peptides undergo several steps until are purified. First, the peptide protected at its N-terminus, 
and its side chain when it is necessary, is attached chemically to a solid polymer, Rink Amide- MBHA 
resin in the case of this work, following repetitive cycles of deprotection and coupling to a next amino 
acid, until have a synthesized desired peptide. Then, the peptide is ready to be cleaved from the resin 
to be purified and characterized. [43] 
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Figure 2.3- Scheme of main Steps of SPPS 
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Sample preparation 
The peptide used in this work was t C16K3, composed by 3 lysines and palmitic acid as a tail, as shown 
in figure 2.4 and it was synthesised manually once the peptide is very small. It was synthesized on a 1 
mmol scale, by SPPS 
Lysine (abbreviated as Lys or K) is an amino acid with a very polar side chain that makes it highly 
hydrophilic. This amino acid is positively charged at neutral pH, since it contains amino groups (NH2) 
which can be protonated (NH3
+), so it is easier to penetrate into the cells as cell membrane is 
negatively charged. 
 
Figure 2.4 - Structure of C16K3 peptide attached to MBHA resin 
 
This PA was already protected (Fmoc-Lys(Boc)-OH) and during its synthesis was washed with 
dimethylformamide (DMF) and dichlorometane (DCM) between each cycle of deprotection and coupling. 
At the end of each cycle, Kaiser test was performed. A blue color was obtained after each 
deprotection, meaning that they are free amines and yellow color at the end of each coupling ensuring 
that the amine group has been occupied. 
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The last step is called cleavage and was performed by acidolysis with strong acid, TFA (trifluoro 
acetic acid), using a cleavage cocktail composed by 2,5% of water, 2,5% of triisopropylsilane (TIS) and 
95% of TFA. In this step, the resin was cleaved from the peptide and also the protecting groups of the 
side chain were removed, leaving the peptide free. 
After that, is important to remove the remaining TFA of the previous step which can be toxic to cells. 
It was removed on a rotary evaporator under vacuum (850 mbar). 
 
2.2. Peptide characterization and purification  
After these steps, the free peptide was analysed by analytical high performance liquid 
chromatography (HPLC) and purified by preparative HPLC by reverse-phase method. For peptide 
identification, mass determination by electrospray ionization mass spectrometry (ESI-MS) was used. 
 
2.2.1. High Performance Liquid Chromatography (HPLC) 
HPLC is a technique able to separate the compounds in a mixture, identifying and quantifying each 
component. 
This technique is based on a reservoir with solvents, a pump to move the solvent continuously 
creating a mobile phase with a desired flow rate through the column, an injector which inject the 
sample that is carried into the high pressure column (stationary phase) by the mobile phase stream, a 
detector, based on mass spectroscopy or UV for example, to observe the signals of each compound 
sending to a computer that records the signals and generate a chromatogram providing data analysis. 
[45] 
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Figure 2.5 - Scheme of HPLC system. Adapted from [45] 
The samples are liquid (solubilized in the solvent which is going to be used in mobile phase) and, 
before injected in the system, are filtered.  
Once prepared, the sample is ready to run and when is injected it flows until reach the column 
leaving the mobile phase and enters in stationary phase where separation takes place depending on the 
mode used. 
In the Normal-Phase, the stationary phase is polar (silica), relevant to substances insoluble in water. 
On the other hand, the Reverse-Phase, used in the present work, is the chromatography mode in which 
the stationary phase has low polarity and is used a polar mobile phase (water, buffer solutions, etc.) 
[45] 
The Reverse-Phase has better resolution, higher viability to separate ionic samples, utilizes the 
column typically C18 which enables analysis from water-soluble and/or ionic substances to lipophilic 
substances. 
The separation occur based on polarity of the compounds. Inside the column, first eluting polar 
substances which have lower interaction with apolar stationary phase. 
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Figure 2.6 - Representation of a Reverse-Phase Chromatography column showing three analyte bands 
with different speeds of elution. Adapted from [45]  
The figure 2.6 represent a sample with a mixture of yellow, red and blue dyes which moving at 
different speeds through the column, due to higher or lower attraction to the polar mobile phase. The 
yellow dye elute faster than the others due to it higher polarity and so, higher attraction to the solvent 
(mobile phase). 
Besides of identification and quantification of compounds present in a mixture, this technique can 
also select desired amounts of each compound to purify the sample. This is performed in so-called 
preparative HPLC that operates in a higher scale than analytical HPLC. The preparative HPLC contains a 
fraction collector that collects purified fractions which are isolated from impurities. 
 
Sample preparation 
The C16K3PA, after being dissolved in water and freeze-dried, was prepared to be analysed in 
analytical HPLC A sample was dissolved in 0,1% TFA in water with a concentration of 1 mg/ml and 
filtered into specific vials. 
A mass spectroscopic detector was used, which is based on chemical compounds that generate 
charged molecules by ionization which are separated on basis of their mass to charge. The column used 
was Waters XBridge column, designed to provide excellent conditions for acidic and basic mobile 
phases, and applied a flow rate of 1.0 ml/min. 
The gradient used, Gene 45 minutes and the solvents injected for the first 32min was 0.1% TFA in 
water (98%) and 0.1% TFA in acetronitrile (2%), Which was Increasing until at Reached 100% at 35min. 
After this time, has been decreased to return to initial conditions. 
In order to purify the peptide, the sample was run in preparative HPLC which was operated with a 
flow rate of 20.0 ml/min. 
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After that, the peptide undergone treatment processes with HCl to exchange TFA ions, coming from 
the preparative HPLC, followed by a dialysis to remove salts. 
 
2.2.2. Electrospray Ionization Mass Spectrometry (ESI-MS) 
For peptide identification and characterization, mass spectrometry is a powerful technique due to 
their sensitivity and since has the ability to provide highly accurate molecular weight information. [46]  
The determination of mass is possible by ionization, without fragmentation, through different 
methods and occurs through the addition (positive ionization mode) or removal (negative ionization 
mode) of protons. 
ESI-MS is composed by an ion source where the ions are produced and transferred in the mass 
analyser which are separated according to their mass to charge ratio (m/z value) and are detected in 
detector system to measure their concentration and a mass spectrum is displayed. [47] (figure 2.7 a)) 
The peaks on mass spectrum represents the intact molecule with variable charging, as shown in figure 
2.7 b). 
 
 
Figure 2.7 - a) Components of ESI-MS. All the components are kept at very high vacuum since the 
ions in gas-phase are very reactive and have short life [47]; b) Mass spectrum of a peptide in positive 
and negative ionization mode [46]  
 
Sample preparation 
The peptide, for mass analysis, was dissolved in methanol at to 0,1 mg/ml and filtered into specific 
vials and was performed before and after purification. 
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The masses of main possible fragments were previously calculated, to compare the values. 
 
2.3. Critical micelle concentration 
The purified peptide, when in aqueous solution, is able to form micelles since it is a surfactant, 
amphiphilic molecule, which contains a hydrophilic head and a hydrophobic tail. 
At low concentration, the molecules line up on the air-water interface with the hydrophilic region in 
contact with water as shown in figure 2.8. Increasing the surfactant concentration, the interfacial 
tension, called surface tension, decrease and the surface becomes saturated leading to the micelle 
formation. [48]  
 
Figure 2.8 – Behaviour of amphiphilic molecule in aqueous environment. A) Structure of amphiphilic 
molecule; B) Amphiphilic molecule on air-water interface; C) Micelle with hydrophobic tail inside. 
Adapted from  
 
This surfactant concentration above which micelles are formed is called critical micelle 
concentration (CMC) and it is important to study their stability. Many studies has been shown a reverse 
relationship between the CMC and hydrophobicity, concluding that the higher hydrophobic part length 
lower is CMC.[49]  
According to the literature, generally, polymeric micelles show CMC values at around 10-6 or 10-7 M. 
[23] 
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There are different techniques to measure this concentration. In this work it was measured by 
fluorescence spectroscopy. 
 
2.3.1. Fluorescence spectroscopy 
Fluorescence is the emission of a photon, of lower energy, resulted when the molecule relaxes 
through vibrational relaxation and returns to ground electronic state, after being excited. So, when 
one molecule in the normal electronic state, the lowest vibrational level, absorb light is elevated to 
produce excited states. Then, the molecule can return to any level of the ground state, emitting its 
energy in the form of fluorescence. [50, 51] Figure 2.9 represents a diagram showing both absorption 
and fluorescence and levels of excited states. 
 
Figure 2.9 - Jablonski diagram representing the absorption of light (purple); vibrational relaxation, 
where no photon is emitted and the energy is dispersed to the solvent as heat or vibrations (green) and 
fluorescence (yellow) 
This measurement was performed in a Fluorescence 
Spectrometer LS55, as shown in figure 2.10. A 
fluorimeter contains a source of light, two 
monochromator, a sample holder and a detector. 
The radiation in the UV, visible or near-infrared 
regions is emitted in the lamp source, being the most 
commonly used aXenon arc lamp.  
Figure 2.10 - Fluorescence Spectrometer LS55- 
QMUL 
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The light achieves first monochromator, which allows the preselection of the excitation wavelength, 
and passes through the sample holder where the sample is inside of a special cuvette. Then, the 
molecules in the solution after being excited emit light which is analysed by the emission 
monochromator. 
The photomultiplier tubes, which are used as detector, receive the emitted light of the preselected 
wavelength and measure their intensity. [51]  
The scheme, in figure 2.11, shows one example of instrument status. 
 
Figure 2.11 – Scheme of instrument status representing the individual components and current setup 
of the instrument  
 
Sample preparation 
The measurements on fluorescence spectrometer were performed by using Nile Red as a probe 
molecule in order to determine the CMC.  
Nile Red has been recognized as a polarity-sensitive probe with high affinity to the hydrophobic 
regions. This fluorescent molecule, being poorly soluble in water, is expected to show weakly 
fluorescence in aqueous environment but a higher intensity at the CMC, due to micelles formation 
which permit a better solubilisation of the probe. [52, 53] 
Nile Red was dissolved in methanol at 2 mM, diluted to 0,02mM and left overnight to evaporate the 
methanol. Several peptide samples were prepared at different concentrations, as shown in figure 2.12, 
dissolved in water and 100 µL of Nile Red solution was added in each sample to be analysed on 
fluorescence spectrometer. 
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All the steps were done in the dark due to the light sensitivity of the Nile Red. 
All the samples were transferred into a cuvette to be measured on spectrometer. 
The samples were excited at 530 nm and the range of emission wavelengths were included between 
550 nm and 720 nm, since excitation/emission maxima ~552/636nm in methanol  
 
Figure 2.12 - Sample concentrations (mM) analysed by fluorescence spectroscopy 
 
 
After the CMC is known, it is important to determine the size of the micelles and their stability, to 
obtain information on the performance of the micelles. These measurements were performed on 
Zetasizer Nano ZS equipment. 
 
2.3.2. Zetasizer Nano ZS 
Zetasizer is an instrument which provides the ability to measure three fundamental parameters of 
particles or molecules in a liquid medium.is used to 
measure particle and molecule size by dynamic light 
scattering technique, electrophoretic mobility of 
proteins, zeta potential of colloids and nanoparticles 
by electrophoretic light scattering technique and also 
enable the measurement of molecular weight by static 
light scattering technique.  
Figure 2.13 - Malvern Instruments Zetasizer Nano 
ZS- QMUL 
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This work was performed in Zetasizer Nano ZS, as shown in figure 2.13. 
 
 Size Measurement by Dynamic Light Scattering  2.3.2.1.
Determination of the size of nanoparticles in suspension is an important parameter to understand 
these materials in the nano-scale, being important maintaining their characteristics such as optical, 
chemical, thermal or electronic properties. [54, 55]  
Particle size is considered to be the diameter of the sphere that diffuses at the same velocity of the 
particle which is measured. [56]  
In this case, size is one of the most significant characteristic since only small particles can cross the 
BBB and measuring particle size distribution can be critical to reach the brain successfully.  
This property is measured using a process called Dynamic Light Scattering (DLS) which uses a laser as 
a source of monochromatic light to illuminate the solution containing particles in Brownian motion. 
Then, the light, after passed through a collimator lens, which focus the beam, hits these particles 
causing a Doppler Shift and the light scatters in all directions. The scattered light passes through 
another collimator lens which ensures that the amount of light is the desired and is detected at a 
known scattering angle by a photomultiplier. Thus, the diffusion coefficient of the particles is 
measured with autocorrelation function and gives the information about the particles. [57, 58]  
It is known that there is a relationship between speed of movement due to Brownian motion and the 
size of particles in a liquid (Stokes-Einstein equation). The particles in the sample are small if there is a 
quickly movement and the particle positions are quite different.  
As the particles are constantly moving, the intensity of the scattered light appear fluctuate and 
Zetasizer system measures this fluctuation and uses it to calculate the size with a digital correlator. 
The correlation is related with time, comparing two intensity signals at different points in time, being 
1 a perfect correlation, where the time is very short and the signals are identical and 0 when no 
correlation is observed. As mentioned above, the small particles move quickly and fluctuation will also 
faster than if the large particles are being measured. For that reason, the rate decay for the 
correlation function is related to particle size, as shown in figure 2.14. 
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Figure 2.14 - Correlation function related with size of particles. Adapted from [56] 
 
Then, with information of correlation function, the software uses algorithms to generate a size 
distribution, extracting the decay rates for a number of size classes. [56]  
The results are presented in a size distribution by intensity graph, as shown in figure 2.15. It should 
show only one peak meaning that the sample contains only one size of particles. 
 
Figure 2.15 - Typical size distribution plot, showing size classes in X axis and the intensity of 
scattered light in Y axis. Adapted from [56] 
 
Sample preparation 
After determination of the CMC, a PA sample was prepared with a concentration higher than CMC 
value to ensure the micelles are formed. 
 
 38 
The sample was dissolved in 1mL of water at 5 mM and was filtered into a clean cell to avoid any 
possible dust contamination, since this technique is very sensitive to the presence of aggregates or 
large contaminates which is not of interest or can cause result variations. 
The cell was filled slowly to avoid air bubbles from being created. 
 
 Zeta Potential by Electrophoretic Light Scattering  2.3.2.2.
The stability of the particles is another significant issue to study and this is done by measuring the 
zeta potential, determining the electrophoretic mobility, using laser Doppler velocimetry. 
In a solution, the magnitude of electrostatic repulsion or charged between adjacent particles is 
called zeta potential, shown in figure 2.16,and gives an information about the potential stability of the 
colloidal system.  
 
Figure 2.16 - Scheme of the charged surface of a particle in aqueous medium. Adapted from [59] 
 
Thus, when the zeta potential value is low, attractive forces may exceed the repulsion and the 
dispersion tends to coagulate or flocculate. Otherwise, particles with high values of zeta potential, 
negative or positive, are considered stable, mainly > +30 mV or <-30 mV, as shown in table below. [60-
62] 
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Table II - Zeta potential values and correspondent stability behavior of the colloid. Adapted from [61]  
 
 
 
 
 
 
 
 
Electrophoretic Light Scattering (ELS) is based on DLS but, here, the frequency shift is caused by 
oscillating electric field. [63]  
When an electrical field is applied, the charged particles move towards the oppositely charged 
electrode and their velocity is measured and expressed in unit field strength as their mobility. [62, 64] 
This is called electrophoresis and this velocity is measured by analysing resultant light intensity 
frequency by the seeded particles within the flow, as shown in figure 2.17.  
 
Figure 2.17 - Measurement of velocity of particles moving through a fluid in an eletrophoresis 
experiment by laser doppler velocimetry 
Zeta Potential (mV) Stability 
0 to ± 5 Rapid coagulation or 
flocculation 
±10 to ±30 Incipient instability 
±30 to ±40 Moderate Stability 
±40 to ±60 Good Stability 
> ±61 Excellent Stability 
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Once known the velocity of the particle and the electrical field applied, it is possible measure the 
zeta potential using the viscosity and dielectric constant (Henry equation): 
UE= 
           
   
 
  : zeta potential  
 UE: Eletrophoretic mobility 
  : Dielectric constant 
  : Viscosity  
 f(Ka): Henrys function 
 
Sample preparation 
The sample, in this case, was also filtered, eliminating sample cross contaminations, but transferred 
into a special cell with two electrodes, disposable folded capillary cell (DTS1060), shown in figure 2.18, 
to measure the electrophoretic mobility of the particles in solution. 
The sample, at same concentration used in size measurements (5 mM), was transferred to the 
cuvette carefully, using syringes, to avoid bubble formation inside the cell and measurement errors. 
The sample was slowly injected through one of electrodes and covering the other electrode with one 
cap, when the sample starts to emerge. This cap ensures greater thermal stability of the sample and 
can prevent dust contamination and possible spillage. After checking that there were no bubbles, the 
other electrode was also covered with other cap. 
.  
Figure 2.18 – Disposable folded capillary cell.(DTS1060) Adapted from [56] 
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  Chapter 3
Results and discussion 
3.1. Peptide Synthesis and characterization  
C16K3 PA was successfully synthesized, following Solid-Phase Peptide Synthesis protocol, purified using 
preparative HPLC and confirmed by analytical HPLC.  
After the first deprotection to remove Fmoc group, the Kaiser test was shown blue dark, meaning the 
amine group was free, ready to couple the next amino acid. The yellow colour was observed after the 
test, carried out after the first coupling to ensure that was well-done. The yellow colour means that 
the amine group was occupied and the coupling was done as desired. The same happened for the 
following amino acids, except for the tail which was more difficult to attach to the peptide. 
Figure 3.1 shows the analytical HPLC chromatogram before purification and figure 3.2 after 
purification. 
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Figure 3.1 – Chromatogram (analytical HPLC) of the crude peptide 
 
Figure 3.2 – Chromatogram (analytical HPLC) of the pure peptide 
 
In the analytical HPLC, after purification, it was observed only one peak, representing the peptide in 
the sample, concluded that the peptide was with high purity, since no other components were 
observed in the sample. 
The retention time was around 20 min which means that the peptide takes this time to elute from 
the column after injection. According to the gradient used, C16K3 PA only started to leave the column 
with the addition of 0,1% TFA+ acetronitrile through the column. This means that the peptide, despite 
being water soluble, didn’t elute early, when the solvent was totally polar (0,1%TFA in water), due to 
the hydrophobicity of the peptide tail which has affinity to apolar stationary phase. 
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Figure 3.3 – Mass spectrum of C16K3 PA, after peptide purification 
 
Table III – Expected and observed mass to charge ratio of the main fragment ions of C16K3 peptide 
Peptide Molecular 
weight (g/mol) 
 
C16K3 639.97 [M+1H]
+ [M+2H]2+ [M+3H]3+ 
Expected mass (m/z) 640.97 320.99 214.32 
Observed mass (m/z) 640.4 320.6 ___ 
 
The results of mass spectrometry is a spectrum, where are represented peaks characterized by mass-
to-charge ratio (m/z) of smaller peptide fragments, coming from ionization, and intensity value which 
is the number of detected fragments.  
In figure 3.3, it is possible to see, two main peaks meaning that the peptide have one and two sites 
of protonation. The first peak, with 320.6 m/z, represents a doubly charged fragment ion, i.e., the 
charge state of the fragment is +2 and the second peak, with 640.4 m/z means that less fragments are 
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singly charged (+1). These values were the expected for this peptide, previously calculated, as shown 
in table III. 
3.2. Fluorescence Spectroscopy 
The CMC was evaluated by fluorescence spectroscopy and due to the lower water solubility of Nile 
red, shifts in the fluorescence intensity and corresponding emission maximum wavelength were 
observed. For C=CMC, there is a sharp increase in fluorescence intensity and a hypsochromic effect 
(blue shift). This blue shift, a decrease in wavelength with a corresponding increase in frequency was 
observed in figure 3.4. 
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Figure 3.4 - Fluorescence measurements of samples with concentrations between 0,002 mM and 10 mM 
showing different fluorescence intensity scale, a) in a range 0-140 AU; b) 0-20 AU 
 
Observing the graphs of fluorescence, it is clear a change in intensity in fluorescence for samples with 
higher concentrations. This occurs because at these concentrations, the PA starts to form micelles in 
aqueous environment and, due to its hydrophobicity, the used dye is incorporated into micelle pocket. 
To measure the CMC point, the concentration of the different samples was plotted against the 
maximum intensity and correspondent wavelength (figure 3.5), suggesting a CMC value around 4 mM, 
meaning micelle formation only from this value. This CMC value is lower than the other systems 
previously studied, such as polymeric micelles, in the range between 10-6 or 10-7 M of, mentioned in the 
previous chapter. 
 
Figure 3.5 - Offset of I_max and WL at I_max vs Log(Concentration at mM), using OriginPro 9 
software 
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3.3. Zetasizer nano ZS 
3.3.1. Size measurements  
The results of size measurement are shown in figure 3.6 with two peaks meaning that there were 
particles with two different sizes in the sample. 
 Since the length of the C16K3 PA molecule is around 5 nm, estimated in ChemDraw software, and 
based on other studies with peptide amphiphile micelles, is possible say that the small peak at around 
12 nm is about micelle structure and the larger one can be vesicles forming also by self-assembly.  
 
 
Figure 3.6 – Intensity stands for particle size distribution and the details of the peaks 
 
This result shows controlled micelle size and small enough for drug delivery into the brain, since less 
than 100 nm is ideal to cross the BBB. 
3.3.2. Zeta potential measurements  
The value of zeta potential measurement was 60.8 mV, meaning, according table II of the previous 
chapter, a good stability of the micelles. 
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  Chapter 4
Conclusions and future works  
The C16K3 PA, successfully synthesized and purified, was able to form micelles, easily, in aqueous 
environment, showing low CMC values, which is one advantage of these systems, as well as, their great 
stability in solution and appropriate size for drug delivery into the brain. 
The fact of the peptides amphiphile are easy to synthesize, forming micelles easily, by self-assembly, 
stable and small enough to cross the BBB, and well organized structure, with multiple domains, makes 
them a good candidate to act as nanocarrier to transport drugs and reach the brain. 
To assist their transport and minimizing their side effects, these systems are advantageous over the 
others already developed, previously mentioned in this thesis, due to the possible incorporation of 
targeting sequences into the peptide, without further complex modifications on surface.  
For future works, the next step will be the loading of the drug into C16K3 PA and the study of drug 
release in order to better understand the mechanism and to ensure a controlled release. 
In order to assist their transport across the BBB and reach the target sites, will be incorporated 
targeting sequences, for instance, ligand for specific receptors of BBB which can be overexpressed in 
pathological conditions.  
And, finally, testing the peptide as nanocarrier, in vitro, mimicking biological conditions with BBB 
models. 
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